Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | Analysis of JAK inhibitors and risk of secondary B-cell lymphomas in MPN patients

Naveen Pemmaraju • 15 Jun 2019
EHA 2019
Myeloproliferative Neoplasms

Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses his group’s latest work on JAK inhibitors and the risk of secondary B-cell lymphomas in patients with myeloproliferative neoplasms (MPNs). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Naveen Pemmaraju

The value and interactive format of the MPN Workshop of the Carolinas
6:05
The value and interactive format of the MPN Workshop of the Carolinas
Naveen Pemmaraju • 22 Aug 2025
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
2:06
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju • 15 Jun 2025
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
1:55
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
Naveen Pemmaraju • 31 May 2025
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV
2:17
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV
Naveen Pemmaraju • 31 May 2025

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Naveen Pemmaraju • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Naveen Pemmaraju • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Naveen Pemmaraju • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Naveen Pemmaraju • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals